Role of nutrient-sensing taste 1 receptor (T1R) family members in gastrointestinal chemosensing

Soraya P. Shirazi-Beechey1*, Kristian Daly1, Miran Al-Rammahi1, Andrew W. Moran1 and David Bravo2

1Epithelial Function and Development Group, Department of Functional and Comparative Genomics, Institute of Integrative Biology, University of Liverpool, Liverpool L69 7ZB, UK
2Pancosma SA, Geneva, Switzerland

(Submitted 26 February 2013 – Final revision received 8 April 2013 – Accepted 11 April 2013)

Abstract
Luminal nutrient sensing by G-protein-coupled receptors (GPCR) expressed on the apical domain of enteroendocrine cells activates intracellular pathways leading to secretion of gut hormones that control vital physiological processes such as digestion, absorption, food intake and glucose homeostasis. The taste 1 receptor (T1R) family of GPCR consists of three members: T1R1; T1R2; T1R3. Expression of T1R1, T1R2 and T1R3 at mRNA and protein levels has been demonstrated in the intestinal tissue of various species. It has been shown that T1R2–T1R3, in association with G-protein gustducin, is expressed in intestinal K and L endocrine cells, where it acts as the intestinal glucose (sweet) sensor. A number of studies have demonstrated that activation of T1R2–T1R3 by natural sugars and artificial sweeteners leads to secretion of glucagon-like peptides 1&2 (GLP-1 and GLP-2) and glucose dependent insulinotropic peptide (GIP). GLP-1 and GIP enhance insulin secretion; GLP-2 increases intestinal growth and glucose absorption. T1R1–T1R3 combination co-expressed on the apical domain of cholecystokinin (CCK) expressing cells is a luminal sensor for a number of L-amino acids; with amino acid-activation of the receptor eliciting CCK secretion. This article focuses on the role of the gut-expressed T1R1, T1R2 and T1R3 in intestinal sweet and L-amino acid sensing. The impact of exploiting T1R2–T1R3 as a nutritional target for enhancing intestinal glucose absorption and gut structural maturity in young animals is also highlighted.

Key words: T1R1-T1R3; T1R2-T1R3; Intestine: sensing: SGLT1: GLP-2: CCK

G-protein-coupled receptors (GPCR) represent the largest family of cell-surface mediators of signal transduction(1). GPCR have attracted significant attention in terms of continued identification and characterisation, with recognition that they are targets for novel drug discovery. With more recent evidence demonstrating that nutrient sensing in the gastrointestinal tract is accomplished by a number of GPCR(2), the role of these receptors as important nutritional targets is becoming evident.

Nutrient-sensing GPCR for a variety of nutrients have been identified in the intestinal epithelium. They are expressed on the apical domain of enteroendocrine (sensor) cells of the gut and are directly activated by nutrients(3–5). Nutrient sensing initiates a cascade of events involving hormonal and neural pathways. This culminates in functional responses that ultimately regulate vital processes such as nutrient digestion and absorption, food intake, insulin secretion and metabolism.

This brief article focuses on the role of the taste receptor 1 family of GPCR, T1R1, T1R2, and T1R3, in sweet and L-amino acid sensing, with particular focus on its role in glucose absorption, glucose homeostasis and satiety. Moreover, the impact of exploiting the T1R2–T1R3 heterodimer as a nutritional target for enhancing intestinal glucose (salt and water) absorption and gut structural maturity in young animals is highlighted.

Sweet and L-amino acid sensing in the lingual epithelium
The T1R family present in the taste cells of the lingual epithelium consists of three members: T1R1; T1R2; T1R3(6,7). These receptors are distantly related to metabotropic glutamate receptors (mGlur), extracellular Ca2+-sensing receptor (CaSR) and γ-aminobutyric acid type B receptor(8). Based on electrophysiological studies, heterologous expression of taste receptor subunits and behavioural assays of knockout mice, the heterodimeric combination of T1R2–T1R3 has been shown to function as a broad-specificity sweet sensor for natural sugars, sweet proteins and artificial sweeteners, whereas the combination of T1R1–T1R3 has been identified as a broad-spectrum

Abbreviations: CaSR, Ca2+-sensing receptor; CCK, cholecystokinin; GIP, glucose-dependent insulinotropic peptide; GLP, glucagon-like peptide; GLUT, glutamate; GPCR, G-protein-coupled receptors; IMP, monophosphate esters of inosine; LEU, leucine; PHE, phenylalanine; SGLT1, Na+/glucose cotransporter-1; T1R, taste receptor 1; TRP, tryptophan.

* Corresponding author: S. P. Shirazi-Beechey, email spsb@liverpool.ac.uk
l-amino acid sensor, responsible for mediates the perception of the savoury ‘umami’ taste of monosodium glutamate\(^{11,12}\). Both the T1R2–T1R3 and T1R1–T1R3 heterodimers are coupled to the heterotrimERIC G-protein gustducin to transmit intracellular signals\(^{13}\).

In rodents and many other mammalian species, the lingual epithelium T1R1–T1R3 heterodimer responds to most of the twenty standard l-amino acids in the millimolar range\(^{12}\). However, the T1R1–T1R3 heterodimer is not activated by l-tryptophan (TRP)\(^{12}\). The human T1R1–T1R3 complex functions as a much more specific receptor, responding selectively to monosodium glutamate (GLUT) and aspartate (as well as to the GLUT analogue L-AP4)\(^{10,11}\). A salient feature of amino acid taste in animals and umami taste in humans is the synergistic enhancement of potency when GLUT or other amino acids combine with the monophosphosphate esters of inosine or guanosine nucleotides (IMP and GMP)\(^{14–16}\). Both GLUT and IMP/GMP bind to adjacent domains on the N-terminal Venus flytrap module of T1R1\(^{17}\), while potentiation of intracellular signal transmission by IMP is mediated through α-gustducin\(^{18}\).

Gurmarin, a thirty-five-residue polypeptide from the Indian-originated tree Gymnema sylvestre (Gurmar), can inhibit both sweet and l-amino acid sensing by binding to the Venus flytrap domain of T1R3, inhibiting its function\(^{19–24}\).

### Intestinal sweet sensing

Work carried out in many laboratories has demonstrated that T1R family members and gustducin are co-expressed in enteroendocrine cells in a range of species\(^{5,7,24–33}\), suggesting that taste-sensing mechanisms exist in the gastrointestinal tract.

It is well established that enteroendocrine L and K cells secrete glucagon-like peptides (GLP) (1 and 2) and glucose-dependent insulino-tropic peptide (GIP), respectively, on encountering glucose in the intestinal lumen. GLP-1 and GIP, known as incretins, enhance insulin secretion, while GLP-2 increases intestinal growth and glucose absorption\(^{34–36}\). The infusion of intestinal lumen with the α-isosforms of glucose, galactose and fructose and non-metabolisable analogues of glucose, 3-O-methyl-glucose and α-methyl-glucose, cause the secretion of GIP and GLP-1 in rats, pigs and humans\(^{37–39}\). Furthermore, it has been shown that the T1R2–T1R3 heterodimer together with the α-subunit of gustducin resides in K and L endocrine cells containing GIP, GLP-1 and GLP-2, respectively\(^{7,8,30,35}\).

Functional evidence for the role of the T1R2–T1R3 heterodimer in intestinal glucose (sweet) sensing, inducing GLP-1, GLP-2 and GIP release, has been provided using endocrine cell lines, native intestinal tissue explants and knockout mice deficient in α-gustducin or T1R3\(^{7,24,52,35}\). The murine endocrine cell line GLUTag exhibits markedly increased GLP-1 secretion upon exposure to the artificial sweetener sacralose; this secretion is blocked by gurmarin, indicating that sacralose-induced GLP-1 release occurs through the activation of the T1R2–T1R3 heterodimer\(^7\). Similar results were obtained for sacralose-induced GLP-1 release in the human L endocrine cell line NCi-H716, which was blocked either by RNA interference targeting of α-gustducin or by the human sweet taste receptor antagonist lactisole\(^{53}\). Furthermore, the plasma levels of GLP-1 and GIP following the introduction of glucose directly into the proximal intestine are reduced in α-gustducin or T1R3 knockout mice, compared with wild-type controls\(^{40}\). Moreover, these knockout mice have abnormal insulin profile and prolonged postprandial blood glucose responses in response to luminal glucose\(^{40}\). Further work carried out by Geraedts et al.\(^{52}\) has shown that luminal glucose, fructose or sucralose evoke release of GLP-1 from mouse ileal explants embedded in an Ussing chamber, and that secretion of GLP-1 does not occur in tissue explants from T1R3 knockout mice\(^{42}\). Moreover, exposure of mouse intestinal explants to either glucose or sucralose results in the secretion of GLP-1 and GLP-2, in a dose-dependent manner, and that this secretion is inhibited in the presence of gurmarin, a specific inhibitor of T1R3\(^{53}\) (Fig. 1). Notably, the levels of GLP-1 and GLP-2 released by control and glucose-stimulated tissues were similar to those observed in in vitro studies in rats and human subjects given glucose orally or maintained as controls\(^{41,42}\), supporting the suitability of intestinal tissue explants for such studies.

In these assays, the enteroendocrine cells reside in their native niche, and it appears that maintaining contacts with neighbouring cells is important for enteroendocrine cells to retain their functional viability\(^{43}\). Collectively, the data suggest that the sensing of sugars by the T1R2–T1R3 heterodimer coupled to gustducin expressed in L and K endocrine cells leads to the release of GLP-1, GLP-2 and GIP.

However, there are reports indicating that sweeteners do not trigger the release of incretins. Parker et al.\(^{44}\) have reported that primary cultures of adult mouse intestine do not secrete GIP in response to sucralose. This is not surprising, since they have indicated that these isolated cells do not express the T1R2–T1R3 heterodimer\(^{44}\). There are also reports that oral ingestion or intra gastric infusion of artificial sweeteners does not increase the secretion of incretins in rats\(^{45}\) or humans\(^{46}\). By feeding rats a single concentration of sweeteners (50 mg or 1 g/kg body weight, depending on the sweetener), Fujita et al.\(^{45}\) have concluded that sweeteners do not acutely induce the release of incretin hormones. Ma et al.\(^{46}\) have also reported that 0–4 or 4–16 mm sucralose given by intragastric infusion does not induce the secretion of incretins. Interestingly, lactisole, which inhibits T1R3 function, reduces the blood levels of GLP-1 in humans receiving an intragastric glucose load\(^{47}\).

Many artificial sweeteners are partly absorbed in the stomach and subsequently secreted in the urine\(^{48}\). Therefore, the lack of response observed by these workers may be due to the concentration of the sweeteners being below the threshold level required for activating the candidate receptor and/or the lack of availability of the sweetener at the distinct target region of the intestine. Further work is required to unravel these controversies.

The majority of membrane-bound proteins, including GPCR, are low-abundance proteins\(^{49–53}\). In our experience more sensitive SYBR Green assay rather than TaqMan-based assay and/or increased amounts of template complementary DNA (up to 250 ng/reaction) are effective in detecting the expression of T1R family members, having low abundance.
mRNA. This is perhaps why one or two laboratories have failed to detect the expression of T1R1, T1R2, T1R3 and gustducin in purified primary enteroendocrine cells using quantitative PCR\(^{44,54,55}\). Other factors, such as the prevailing cell isolation conditions or the small proportion of purified L or K cells expressing taste receptor subunits and gustducin, have also been proposed to be responsible for the lack of detection of taste receptor elements in purified primary enteroendocrine cells\(^{56}\).

There are some reports proposing that T1R subunits are expressed in the colon; however, their precise functions require further investigations. Iwatsuki et al.\(^{57}\) have demonstrated the expression of T1R2–LacZ in mouse small and large intestinal explants. Geraedts et al.\(^{52}\) have reported glucose-stimulated GLP-1 secretion from Ussing chamber-embedded large intestinal explants of T1R3, but not T1R2, knockout mice. They have concluded that T1R3-dependent and independent pathways are involved in the regulation of GLP-1 secretion in the colon\(^{52}\).

It should be borne in mind that L cells in the small and large intestines may have different phenotypes. Furthermore, in the lumen of the native colonic tissue, there is hardly any free glucose available. Glucose is rapidly metabolised to SCFA by colonic microbiota. SCFA induce the release of GLP-1 via colonic endocrine L-cell GPR43 (FFAR2)\(^{58}\). Therefore, studies directed at the sensing of nutrients in the hindgut must always consider the digestive activity of the microbiota.

**Mechanisms underlying intestinal sweet sensing and glucose transport regulation: application to the maintenance of gut health in weaning piglets**

The major route for the absorption of dietary glucose (and galactose) from the lumen of the intestine into enterocytes is via the apical membrane Na\(^+\)/glucose cotransporter-1 (SGLT1)\(^{59–62}\). The absorption of glucose by SGLT1 also activates salt (NaCl) and water absorption; this is used as the route for oral rehydration therapy\(^{63}\). Thus, the regulation of SGLT1 is essential for the provision of glucose to the body and avoidance of intestinal malabsorption. A number of studies\(^{60,61,64–67}\) have established that the expression of intestinal SGLT1 is enhanced in response to a range of monosaccharides, including non-metabolisable analogues of glucose. Furthermore, it has been shown that the pathway underlying monosaccharide-enhanced SGLT1 expression involves a luminal membrane GPCR glucose sensor\(^{66}\).

Convincing evidence for the involvement of gut-expressed T1R2–T1R3 heterodimer and gustducin in intestinal sweet transduction and SGLT1 regulation has been provided by studies using mice in which the genes for either α-gustducin or the sweet receptor subunit, T1R3, had been deleted. The elimination of sweet transduction in mice in vivo has been shown to prevent the dietary monosaccharide-induced up-regulation of SGLT1 expression that is observed in wild-type mice\(^7\). Furthermore, it has been demonstrated that artificial
sweeteners when included in the diet also enhance the expression of SGLT1(7). In cats (Felidae family) and chickens, naturally occurring ‘T1R2 knockout’ models, there is a good correlation between the absence of T1R2 expression and the inability to increase SGLT1 expression in response to increased dietary sugars(50,68,69). All together, the data support the notion that the T1R2–T1R3 heterodimer, in association with gustducin, senses dietary sugars to regulate the expression of intestinal SGLT1(7).

To unravel the underlying mechanism by which sugar activation by the T1R2–T1R3 heterodimer, expressed on the apical domain of endocrine cells, leads to the up-regulation of SGLT1 expression in neighbouring enterocytes, the underlying chemosensing mechanism has been investigated. It is well established that systemic infusion of GLP-2 enhances intestinal growth and SGLT1 expression(35,36,70–72). Moreover, it has been demonstrated that in vivo vascular infusion of GLP-2 increases, with a similar magnitude, the maximal rate of Na+-dependent glucose transport, Na+-dependent phlorizin binding and SGLT1 protein abundance in the intestinal brush border membrane. This GLP-2 effect was inhibited by brefeldin A73–75, suggesting that GLP-2, increases the number if SGLT1 protein molecules in the brush border membrane(72).

As shown in Fig. 1, the exposure of mouse small intestinal explants to glucose or sucrose evokes the secretion of GLP-2, in a dose-dependent manner, which is inhibited in the presence of guamin, indicating that glucose/sucrose-induced GLP-2 release occurs via the activation of the T1R2–T1R3 heterodimer. Since the GLP-2 receptor is expressed in enteric neurons(76) and not in absorptive enterocytes, a direct paracrine effect of GLP-2 on the neighbouring enterocytes is excluded. The knowledge that direct administration of GLP-2 to enteric neurons induces a neuronal response(76,77) and that electric stimulation of enteric neurons results in the up-regulation of SGLT1 expression, which is inhibited by nerve blocking agents (our own observation), implies that the binding of GLP-2 to its receptor in enteric neurons stimulates a reflex response that results in increased functional expression of SGLT1 in absorptive enterocytes.

Impact

With an intensive livestock production, a shorter suckling period increases productivity in terms of numbers of piglets born. However, early weaning has adverse effects on the intestinal function of piglets, leading to nutrient malabsorption, diarrhoea, malnutrition and dehydration(78–80). A number of field trials (involving more than 4500 piglets) have shown that artificial sweeteners, included in piglet feed, are effective in preventing post-weaning intestinal disorders, enhancing the growth and well-being of early-weaned piglets(72). It is notable that despite the increased palatability of feed containing artificial sweeteners, no steady increase in feed intake has been observed. However, a consistent enhancement of feed conversion efficiency (i.e. kg body mass gained per kg feed intake) has been observed, and the reason for this, until recently, was unknown. The understanding of the molecular basis by which artificial sweeteners enhance gut structural maturity and increase intestinal glucose (salt and water) absorption has led to an effective utilisation of sweeteners as dietary supplements, routinely included in the diet of early-weaned piglets to prevent post-weaning intestinal disorders.

Intestinal sensing of L-amino acids

Protein hydrolysates, peptides and amino acids elicit the secretion of cholecystokinin (CCK) both in vitro and in vivo(82–91). CCK plays a variety of roles in digestive processes, such as slowing of gastric emptying, mediation of intestinal motility and stimulation of pancreatic and gall bladder secretions(92–95). It also inhibits food intake in a manner consistent with a role in satiety(96). Amino acids, in particular L-phenylalanine (PHE), at physiological concentrations (10–50 mmol/l) increases plasma CCK levels and reduce food intake in humans, monkeys, dogs and rodents(99–102). Leucine (LEU), a branched-chain amino acid, induces the release of CCK in cats(103).

T1R1 and T1R3 are expressed in mouse intestinal tissue(24,26,31) and in mouse enteroendocrine STC-1 cells(24). Immunohistochemistry, using triple immunolabelling, has demonstrated co-expression of T1R1, T1R3 and CCK in the same endocrine cell in the mouse proximal intestine(24). Furthermore, confocal microscopy has shown the expression of T1R1/T1R3 to be confined to the apical region, with CCK residing at the basal domain of the same endocrine cells. Immunohistochemical localisation, using double immunolabelling, of mouse proximal intestinal serial sections has confirmed that T1R1 is not expressed by S, K or L endocrine cells and that T1R1 expression is confined to CCK-containing I cells(24). The enteroendocrine cells containing CCK also possess T1R1, T1R3 and α-gustducin(24).

Functional evidence for the role of the T1R1–T1R3 heterodimer in intestinal l-amino acid sensing and eliciting CCK release has been provided by using the STC-1 cell line and mouse proximal intestinal explants. The exposure of STC-1 cells to the individual l-amino acids PHE, TRP, LEU and GLUT provokes the secretion of CCK(24). In contrast, the D-isomers of these amino acids have no effect, providing supportive evidence for the specific effect of l-isomers on the induction of CCK secretion. Furthermore, the inhibition of T1R1 expression in STC-1 cells by RNA interference leads to a significant decrease in CCK secretion in response to PHE, LEU and GLUT, but not to TRP(24). TRP is a high potency activator of CaSR(104), but inactive for the T1R1–T1R3 heterodimer(12). IMP, the specific potentiator of the T1R1–T1R3 heterodimer, significantly enhances the release of CCK by STC-1 cells in response to PHE, LEU and GLUT, but not to TRP. Moreover, pre-incubation of STC-1 cells with guamin inhibits the secretion of CCK significantly in response to PHE, LEU and GLUT, but has no effect on TRP-induced CCK release(24), collectively indicating that the T1R1–T1R3 heterodimer functions as a sensor for PHE-, LEU- and GLUT-induced CCK release in STC-1 cells.
Mouse proximal intestinal explants secrete CCK in response to PHE, LEU and GLUT and this secretion is enhanced by the addition of IMP. However, IMP has no effect on TRP-induced CCK secretion. Moreover, the release of CCK in response to PHE, LEU and GLUT, but not to TRP, is inhibited dramatically by pre-incubation of the tissue with gurmarin(24). Therefore, the functional properties and cellular location of gut-expressed T1R1–T1R3 heterodimer support its role as a luminal sensor for l-amino acid-induced CCK secretion in mouse proximal intestine.

Using isolated and purified mouse mucosal enhanced green fluorescent protein-expressing CCK cells, Wang et al.(105) and Liou et al.(106) have shown that aromatic amino acids l-PHE and l-TRP stimulate the release of CCK through CaSR(105,106). We have shown that the addition of a CaSR antagonist, NPS2143, inhibits PHE-stimulated CCK release partially and TRP-induced CCK secretion totally in mouse proximal intestinal tissue explants, with no effect on LEU- or GLUT-induced CCK secretion (see Fig. 2). The partial and total inhibition of CaSR-mediated PHE- and TRP-induced CCK secretion is consistent with data presented by Wang et al.(105) using purified CCK–enhanced green fluorescent protein cells in the presence and absence of another CaSR antagonist, Calhex 231(105).

Therefore, it appears that both receptors T1R1–T1R3 and CaSR are capable of sensing L-PHE. Interestingly, in support of this, the addition of NPS2143 together with gurmarin totally inhibits PHE-induced CCK release from mouse proximal intestinal tissue(24) (see Fig. 2). The experimental data suggest that CaSR acts as an intestinal amino acid receptor specifically sensing l-aromatic amino acids, while the T1R1–T1R3 heterodimer responds to a number of amino acids provoking CCK secretion.

Nutrient sensing GPCR are attractive and orally accessible targets for manipulations by functional foods and supplements. This has applications for maintaining health and preventing disease.

Acknowledgements

S. P. S.-B. acknowledges the University of Liverpool, the Wellcome Trust and Pancosma for providing financial support. The authors thank peer reviewers for providing constructive and critical comments. The authors’ contributions are as follows: K. D., M. A.-R. and A. W. M. carried out the experiments; D. B. provided scientific and practical advice; S. P. S.-B. wrote the article. S. P. S.-B., K. D., M. A.-R. and A. W. M. declare no conflicts of interest. D. B. is an employee of Pancosma.

References


![Fig. 2. Effect of calcium-sensing receptor antagonist NPS2143 on l-amino acid-induced cholecystokinin (CCK) release by mouse proximal small intestine.](https://www.cambridge.org/core/).


65. Hira T, Maekawa T, Asano K, et al.


